Skip to main content
. 2019 Jun;153(3):541–548. doi: 10.1016/j.ygyno.2019.03.256

Table 3.

Individual patients without progression by 48 months from randomization (total number randomized patients in each group is shown).

Patient number Progression-free time, months Age FIGO stage Performance status No. of chemo cycles No. of maint cycles Confirmed mEOCb
Paclitaxel + carboplatin (n = 13)
1c 50 53 II 0 3 No
2 55 58 III 0 6 Yes
3 59 60 II 1 6 Yes
4 60 55 III 0 6 No



Oxaliplatin + capecitabine (n = 13)
5 51 57 III 0 6 No
6 52 61 II 0 6 Not known
7 63 54 Reca 0 6 Not known
8 85 26 III 0 6 No



Paclitaxel + carboplatin + bevacizumab (n = 11)
9 50 47 II 0 6 0 No
10e 60 55 II 1 6 12 No



Oxaliplatin + capecitabine + bevacizumab (n = 13)
11d 54 31 III 0 6 12 Yes
12 54 50 III 0 6 12 Yes
13 61 48 II 0 6 1 Yes
14 71 58 III 1 6 4 No
15 82 58 II 1 6 12 Yes

Chemo = chemotherapy.

Maint = maintenance with bevacizumab.

a

Recurrence after stage I; no adjuvant chemotherapy given.

b

After central pathology review.

c

Died at 57 months.

d

Died at 56 months.

e

Had doxorubicin/cyclophosphamide 26 months after ending trial treatment (all other patients in the table had no record of subsequent treatment after completing the trial treatment).